Key Developments: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

63.00EUR
15 Aug 2014
Price Change (% chg)

€-1.90 (-2.93%)
Prev Close
€64.90
Open
€65.10
Day's High
€65.10
Day's Low
€62.95
Volume
964,425
Avg. Vol
659,804
52-wk High
€80.93
52-wk Low
€56.30

Search Stocks

Latest Key Developments (Source: Significant Developments)

Merck KGaA Reaffirms FY 2013 Guidance-Conference Call
Tuesday, 6 Aug 2013 08:00am EDT 

Merck KGaA confirmed guidance for fiscal 2013 and expects sales to be in the range of EUR10.7 billion to EUR10.9 billion, EBITDA pre to be in the range of EUR3.1 billion to EUR3.2 billion and EPS to be in the range of EUR8.50 to EUR9.00.  Full Article

BlackRock Inc Increases Stake In Merck KGaA-DJ
Monday, 8 Jul 2013 05:15am EDT 

Dow Jones reported that Merck KGaA said U.S. asset manager BlackRock Inc has increased its stake in the Company and exceeded the threshold of 10% in Merck voting rights on July 3. At that time, BlackRock held 6,464,198 voting rights, which is just over 10%, Merck said.  Full Article

Ablynx NV's and Merck KGaA's Merck Serono's ALX-0761 Nanobody Enters in Phase I Clinical Trial; Ablynx NV to Receive Milestone Payments As Collaborator
Friday, 21 Jun 2013 01:30am EDT 

Ablynx NV announced that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of the Nanobody, ALX-0761, for the treatment of inflammatory diseases. The Phase I study involves a single-centre, randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics and pharmacodynamics of single ascending doses of subcutaneous injections with ALX-0761 in healthy subjects. ALX-0761 is the first clinical Nanobody candidate to emerge from the collaboration which Ablynx NV and Merck Serono entered into in 2008. Ablynx NV has decided to convert the collaboration on ALX-0761 into a license agreement. As a result, Merck Serono has an exclusive worldwide license agreement for ALX-0761 and Ablynx NV is eligible to receive additional development milestone payments associated with the progress of the product in multiple indications as well as regulatory and commercial milestones plus tiered royalties upon approval of the product. The start of the Phase I study triggers a EUR 2.5 million milestone payment to Ablynx NV.  Full Article

Antaria Ltd Announces Supply Agreement With Merck KGaA
Tuesday, 18 Jun 2013 02:57am EDT 

Antaria Ltd announced the finalisation of the supply agreement for Alusion with Merck KGaA. The term of the Merck Agreement is five years commencing with a two year take or pay arrangement. The Merck Agreement contemplates a minimum 50% increase in sales volumes during the two year period. Antaria enjoys a long working relationship with Merck KGaA and the Merck Agreement will reinforce this relationship going forward.  Full Article

EU Regulators May Fine Merck KGaA-Business Standard
Monday, 3 Jun 2013 11:19am EDT 

Business Standard reported that Merck KGaA declined to comment on the reports from Brussels that European Union anti-trust regulators may fine the domestic pharma company for allegedly blocking of entry of cheaper generic medicines in the market. Reports said that Merck KGaA was among the nine companies that are to fined for the allegedly blocking the entry of the generic medicines in the EU.  Full Article

Merck KGaA Raises Low End Of Prior FY 2013 EPS Guidance-Conference Call
Monday, 20 May 2013 08:00am EDT 

Merck KGaA announced that for fiscal 2013 it is narrowing the guidance on earnings per share (EPS). Before the Company guided EPS to be between $8.2 to $9.0 and now it is further refine that to the range of $8.5 to $9.0.  Full Article

AEterna Zentaris Inc Announces Transfer Of Manufacturing Rights Related To Cetrotide To Merck KGaA
Wednesday, 17 Apr 2013 07:30am EDT 

AEterna Zentaris Inc announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA of Darmstadt, Germany (Merck Serono), in all jurisdictions. Subject to the satisfaction of customary closing conditions, the transaction is expected to be completed on or about October 1, 2013, at which time Aeterna Zentaris would receive a one-time payment of EUR2.5 million, or approximately $3.2 million and certain other payments. In addition, the Company has also entered into a transitional services agreement with Merck KGaA under which the Company will, during a 36-month period, provide various transition services to assist Merck KGaA in assuming responsibility for the manufacturing of Cetrotide in consideration for the payment of a monthly fee to the Company throughout such period.  Full Article

Merck KGaA's EMD Serono Appeals Court Decision On Collaboration Agreement With Pfizer Inc
Monday, 15 Apr 2013 08:00am EDT 

Merck KGaA announced that a Pennsylvania appellate court recently decided that the collaboration agreement that EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. entered into in July 2002 for the co-promotion of the multiple sclerosis treatment Rebif (interferon beta-1a) extends until December 31, 2015. EMD Serono, which developed Rebif, had contended that the collaboration should end on December 31, 2013, based on the provisions of the agreement governing extension of the term, and had filed a complaint seeking a court declaration to that end. A lower court ruled that the agreement extends through 2015 and the appellate court affirmed that decision. EMD Serono has asked the appellate court to reconsider ruling. Unless the court grants the request on or before June 7, it will be deemed denied.  Full Article

Merck KGaA to Issue FY 2012 Dividend
Thursday, 7 Mar 2013 01:00am EST 

Merck KGaA announced that it has proposed a dividend of EUR 1.70 per share for the fiscal year 2012, which is up 13% from the dividend for the fiscal year 2011.  Full Article

Merck KGaA's EMD Serono, Inc Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma
Monday, 25 Feb 2013 02:40am EST 

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced that the Phase III CENTRICa trial of the investigational integrin inhibitor cilengitide did not meet primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). CENTRIC includes patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter status. The trial was planned and is being conducted in partnership with the European Organization for Research and Treatment of Cancer (EORTC). Patient safety in CENTRIC was monitored frequently by an independent data monitoring committee and no new or unexpected safety concerns were noted. In prior clinical studies, the most frequently reported adverse events the investigators considered to be attributed to cilengitide included nausea and fatigue. CENTRIC is a randomized, controlled, multicenter, open-label Phase III trial. The trial evaluated the efficacy and safety of cilengitide in combination with temozolomide and radiotherapy in more than 500 patients from 23 countries worldwide with newly diagnosed glioblastoma and methylated MGMT gene promoter status. Patients whose tumors have an unmethylated MGMT gene promoter status are currently being evaluated in the Phase II, randomized, open-label, multicenter COREb trial.  Full Article

BRIEF-Morphosys enters strategic immuno-oncology collaboration with Merck Serono

FRANKFURT, June 12 - Morphosys AG : * Says enters strategic immuno-oncology collaboration * Says Morphosys and Merck Serono enter strategic immuno-oncology collaboration

Search Stocks